Biology of Blood and Marrow Transplantation
Volume 18, Issue 2 , Pages 160-161, February 2012

My AML Cytogenetics Classification Scheme Is Better Than Yours

  • Mikkael A. Sekeres

      Affiliations

    • Corresponding Author InformationCorrespondence and reprint requests: Mikkael A. Sekeres, MD, MS, Director, Leukemia Program, Associate Professor of Medicine, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195.

Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

Received 22 November 2011; accepted 23 November 2011. published online 08 December 2011.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Editorial on Armand et al., “Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study.” BBMT 2011.

PII: S1083-8791(11)00538-6

doi:10.1016/j.bbmt.2011.11.022

Biology of Blood and Marrow Transplantation
Volume 18, Issue 2 , Pages 160-161, February 2012

Article Tools